<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733810</url>
  </required_header>
  <id_info>
    <org_study_id>2R01DK063621-11</org_study_id>
    <secondary_id>R01DK063621</secondary_id>
    <nct_id>NCT01733810</nct_id>
  </id_info>
  <brief_title>The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis</brief_title>
  <official_title>The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dallas VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dallas VA Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on
      the production of inflammatory cytokines that lead to reflux esophagitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reflux esophagitis is thought to be caused by gastric acid that refluxes into the esophagus,
      causing injury. Newer data suggest that reflux of gastric juice into the esophagus
      stimulates HIF-2a, which increases production of inflammatory cytokines.  These cytokines
      are thought to lead to reflux esophagitis. The investigators plan to study the relationship
      of HIF-2a to inflammatory cytokines in patients with known gastroesophageal reflux disease
      and reflux esophagitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>change in esophageal inflammation from baseline to 14 days</measure>
    <time_frame>day 0 and day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>inflammation of the squamous esophageal mucosa will be measured at baseline and at 14 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in HIF-2a levels from baseline to 14 days</measure>
    <time_frame>day 0 and day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amount of HIF-2a present will be measured at baseline and at 14 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Esophagitis</condition>
  <condition>Reflux Esophagitis</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Reflux Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cessation of Acid Suppressing Medications</intervention_name>
    <description>Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.</description>
    <arm_group_label>Reflux Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  U.S Veteran

          -  History of Los Angeles Grade C erosive esophagitis

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Esophageal varices

          -  Warfarin use

          -  Coagulopathy that precludes safe biopsy of the esophagus

          -  Comorbidity that precludes safe participation in the study

          -  Allergy to fluorescein sodium

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart J Spechler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dallas VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry B. Dunbar, MD, PhD</last_name>
    <phone>214-857-1603</phone>
    <email>Kerry.Dunbar@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stuart J. Spechler, MD</last_name>
    <phone>214-857-1603</phone>
    <email>Stuart.Spechler@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stuart J. Spechler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerry B. Dunbar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rhonda Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry B. Dunbar, MD, MPH</last_name>
      <phone>214-857-1603</phone>
      <email>Kerry.Dunbar@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Stuart J Spechler, MD</last_name>
      <phone>214-857-1603</phone>
      <email>Stuart.Spechler@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Ronda Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerry B. Dunbar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 27, 2013</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dallas VA Medical Center</investigator_affiliation>
    <investigator_full_name>Stuart Spechler</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Esophagitis</keyword>
  <keyword>Reflux esophagitis</keyword>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>Acid</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Esophageal squamous cell</keyword>
  <keyword>Reflux</keyword>
  <keyword>Squamous epithelium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
